Jump to ContentJump to Main Navigation
Show Summary Details
More options …

Acta Facultatis Medicae Naissensis

The Journal of Faculty of Medicine in Nis

4 Issues per year

Cite Score 2016: 0.25

SCImago Journal Rank (SJR) 2015: 0.109
Source Normalized Impact per Paper (SNIP) 2015: 0.124

Open Access
See all formats and pricing
More options …

New frontiers of target therapy in oncology: acute promyelocytic leukemia

Ivan Petković / Ivica Pejčić / Svetislav Vrbić
Published Online: 2014-03-25 | DOI: https://doi.org/10.2478/afmnai-2014-0002


By introduction of all-trans retinoic acid (ATRA) in de novo acute promyelocytic leukemia (APL) an revolution in therapy of this disease has been made. The rate of molecular complete remissions (CR) have been doubled compared to conventional chemotherapy with anthracyclines ranging from 90% to 95%. Consolidation therapy is required in order to reduce the risk of early relapse. Maintenance therapy is recommended as it further reduces the risk of relapse, especially in high-risk patients. The relapse rate in APL is relatively high, about 30% and is the most common within three years of starting the treatment. Another agent, arsenic trioxide (ATO) is the optimal drug that achieves high CR rate in relapsed, approximately 80% and hematopoietic stem cell transplantation (HSCT) may prolong the overall survival in patients with APL. ATRA and ATO have become a paradigm of targeted therapy, and APL is a paradigm of curable disease, at least in comparison to other forms of acute myeloid leukemia (AML).


Uvođenjem all-trans retinoične kiseline (ATRA) u de novo akutnoj promijelocitnoj leukemiji (APL) napravljena je revolucija u terapiji ove bolesti. Stopa molekularnih kompletnih remisija (CR) udvostručila se u odnosu na konvencionalnu hemioterapiju antraciklinima i kreće se 90-95%. Konsolidaciona terapija je obavezna radi redukcije rizika od ranog relapsa bolesti. Terapija održavanja je preporučena jer dodatno redukuje rizik od relapsa, pogotovo kod visoko rizičnih bolesnika. Stopa relapsa APL je relativno visoka, oko 30%, i najčešća je unutar tri godine od početka lečenja. Drugi agens, arsen trioksid (ATO) je optimalni medikament koji postiže visoke stope CR u relapsu, oko 80%, a transplantacija matičnih ćelija hematopoeze (TMĆH) može produžiti ukupno preživljavanje bolesnika sa APL. ATRA i ATO su postali paradigma target terapije, a APL paradigma kurabilne maligne bolesti, bar u odnosu na druge forme akutnih mijeloidnih leukemija (AML).

Keywords: acute promyelocytic leukemia; target therapy

Ključne reči: akutna promijelocitna leukemija; ciljana terapija


  • 1. Stone RM, Mayer RJ. The unique aspects of acute promyelocytic leukemia. J Clin Oncol 1990; 8 (11): 1913-21.Google Scholar

  • 2. Warrell RP Jr, de Thé H, Wang ZY, Degos L. Acute promyelocytic leukemia. N Engl J Med. 1993; 329 (3): 177-89. http://dx.doi.org/10.1056/NEJM199307153290307CrossrefGoogle Scholar

  • 3. Davey FR, Davis RB, MacCallum JM, et al. Morphologic and cytochemical characteristics of acute promyelocytic leukemia. Am J Hematol 1989; 30 (4): 221-7. http://dx.doi.org/10.1002/ajh.2830300406CrossrefGoogle Scholar

  • 4. Larson RA, Kondo K, Vardiman JW, Butler AE, Golomb HM, Rowley JD. Evidence for a 15;17 translocation in every patient with acute promyelocytic leukemia. Am J Med 1984; 76 (5): 827-41. http://dx.doi.org/10.1016/0002-9343(84)90994-XCrossrefGoogle Scholar

  • 5. Mertelsmann R, Tzvi TH, To L, et al. Morphological classification, response to therapy, and survival in 263 adult patients acute nonlymphoblastic leukemia. Blood 1980; 56 (5): 773-81.Google Scholar

  • 6. Ventura GJ, Hester JP, Dixon DO, Khorana S, Keating MJ. Analysis of risk factors for fatal hemorrhage during induction therapy of patients with acute promyelocytic leukemia. Hematol Pathol 1989; 3 (1): 23-8.Google Scholar

  • 7. Tallman MS, Lefebvre P, Baine RM, et al. Effects of alltrans retinoic acid or chemotherapy on the molecular regulation of systemic blood coagulation and fibrinolysis on patients with acute promyelocytic leukemia. J Thromb Haemost 2004; 2(8): 1341-50. http://dx.doi.org/10.1111/j.1538-7836.2004.00787.xCrossrefGoogle Scholar

  • 8. Vickers M, M, Jackson G, Taylor P. The incidence of acute promyelocytic leukemia appears constant over most of a human lifespan, implying only one rate limiting mutation. Leukemia 2000; 14 (4): 722-6. http://dx.doi.org/10.1038/sj.leu.2401722CrossrefGoogle Scholar

  • 9. Douer D. The epidemiology of acute promyelocytic leukemia. Best Pract Res Clin Haematol 2003; 16 (3): 357-67. http://dx.doi.org/10.1016/S1521-6926(03)00065-3CrossrefGoogle Scholar

  • 10. Matasar MJ, Ritchie EK, Cosedine N, Magai C, Neugut Al. Incidence rates of acute promyelocytic leukemia among Hispanics, Blacks, Asians and non-Hispanic whites in the United States. Eur J Cancer Prev 2006; 15(4): 367-70. http://dx.doi.org/10.1097/00008469-200608000-00011CrossrefGoogle Scholar

  • 11. Milligan DW, Grimwade D, Cullis JO, et al. Giudelines on the management of acute myeloid leukemia in adults. Br J Haematol 2006; 135 (4): 450-74. http://dx.doi.org/10.1111/j.1365-2141.2006.06314.xCrossrefGoogle Scholar

  • 12. Di Bona E, Avvisati G, Castaman G, et al. Early hemorrhagic morbidity and mortality during remission induction with or without all-trans retinoc acid in acute promyelocytic leukemia. Br J Haematol 2000; 108 (4): 689-95. http://dx.doi.org/10.1046/j.1365-2141.2000.01936.xCrossrefGoogle Scholar

  • 13. Yanada M, Matsushita T, Asou N, et al. Severe hemorrhagic complications during remission induction therapy for acute promyelocytic leukemia: incidence, risk factors, and influence on outcome. Eur J Haematol 2007; 78 (3): 213-9. http://dx.doi.org/10.1111/j.1600-0609.2006.00803.xCrossrefGoogle Scholar

  • 14. De la Serna J, Montesinos P, Vellenga E, et al. Causes and prognostic factors of remission induction failure in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and idarubicin. Blood 2008; 111 (7): 3395-402. http://dx.doi.org/10.1182/blood-2007-07-100669CrossrefGoogle Scholar

  • 15. Fenaux P, Chastang C, Sanz MA, et al. A randomized comparison of ATRA followed by chemotherapy and ATRA plus chemotherapy, and the role of maintenance therapy in newly diagnosed acute promyelocytic leukemia. Blood 1999; 94 (4): 1192-200.Google Scholar

  • 16. Burnett AK, Grimwade D, Solomon E, Wheatley K, Goldstone AH, on behalf of the MRC Adult Leukemia Working Party. Presenting white blood cell count and kinetics of molecular remission predict prognosis in acute promyelocytic leukemia treated with all-trans retinoic acid: result of the randomized MRC trial. Blood 1999; 4131-43.Google Scholar

  • 17. Vahdat L, Maslak P, Miller WH, et al. Early mortality and the retinoic acid syndrome in acute promyelocytic leukemia: impact of leukocytosis, low-dose chemotherapy, PML/RAR-alpha isoform, and CD13 expression in patients treated with all-trans retinoic acid. Blood 1994; 84 (11): 3843-9.Google Scholar

  • 18. Wiley JS, Firkin FC. Reduction of pulmonary toxicity by prednisolone prophylaxis during all-trans retinoic acid treatment of acute promyelocytic leukemia. Australian- Leukaemia Study Group. Leukemia 1995; 9 (5): 774-78.Google Scholar

  • 19. Sanz M, Martín G, González M, et al. Risk adapted treatment of acute promyelocytic leukemia with alltrans- retinoic acid and anthracycline monochemotherapy: a multicenter study by the PETHEMA group. Blood 2004; 103(4): 1237-43. http://dx.doi.org/10.1182/blood-2003-07-2462CrossrefGoogle Scholar

  • 20. Barbey J, Pezzullo J, Soignet SL. Effect of arsenic trioxide on QT interval in patients with advanced malignancies. J Clin Oncol 2003; 21 (19): 3609-15. http://dx.doi.org/10.1200/JCO.2003.10.009CrossrefGoogle Scholar

  • 21. Fenaux P, Le Deley MC, Castaigne S, et al. Effect of all trans retinoic acid in newly diagnosed acute promyelocytic leukemia. Results of a multicenter randomized trial. European APL 91 Group. Blood 1993; 82 (11): 3241-9.Google Scholar

  • 22. Sanz MA, Grimwade D, Tallman MS, et al. Management of acute promyelocytic leukemia: recommendations from an expert on behalf of the Europian LeukemiaNet. Blood 2009; 113 (9): 1875-91. http://dx.doi.org/10.1182/blood-2008-04-150250CrossrefGoogle Scholar

  • 23. Grignani F, Fagiola M, Alcalay M, Longo L, Pandolfi PP, Donti E, Biondi A, Lo-Coco F, Grigniani F, Pellici G. Acute promyelocytic leukemia: from genetics to treatment. Blood 1994; 83 (1): 10-25.Google Scholar

  • 24. Tallman MS, Andersen JW, Schiffer CA, et al. All-transretinoic acid in acute promyelocytic leukemia. N Engl J Med 1997; 337 (15): 1021-8. http://dx.doi.org/10.1056/NEJM199710093371501CrossrefGoogle Scholar

  • 25. Mandelli F, Diverio D, Avvisati G, et al. Molecular remission in PML/RAR alpha-positive acute promyelocytic leukemia by combined all-trans retinoic acid and idarubicin (AIDA) therapy. Blood 1997; 90 (3): 1014-21.Google Scholar

  • 26. Asou N, Adachi K, Tamura J, et al. Analysis of prognotic factors in newly diagnosed acute promyelocytic leukemia treated with all-trans retinoic acid and chemotherapy. Japan Adult Leukemia Study Group. J Clin Oncol 1998; 16 (1): 78-85.Google Scholar

  • 27. Sanz MA, Martín G, Rayón C, et al. A modified AIDA protocol with anthracycline-based consolidation results in high antileukemic efficacy and reduced toxicity in newly diagnosed PML/RARalpha-positive acute promyelocytic leukemia. PETHEMA group. Blood 1999; 94 (9): 3015-21.Google Scholar

  • 28. Lengfelder E, Reichert A, Schoch C, et al. Double induction strategy including high dose cytarabine in combination with all-trans retinoic acid: effects in patient with newly diagnosed acute promyelocytic leukemia. Leukemia 2000; 14 (8): 1362-70. http://dx.doi.org/10.1038/sj.leu.2401843CrossrefGoogle Scholar

  • 29. Adès L, Chevret S, Raffoux E, et al. Is cytarabine useful in the treatment of acute promyelocytic leukemia? Results of randomized trial from the European Acute Promyelocytic Leukemia Group. J Clin Oncol 2006; 24 (36): 5703-10. http://dx.doi.org/10.1200/JCO.2006.08.1596CrossrefGoogle Scholar

  • 30. Burnett AK, Hills RK, Grimwade D, et al. Idarubicin and ATRA is as effective as MRC chemotherapy in patients with acute promyelocytic leukemia with lower toxicity and resource usage: preliminary results of the MRC AML 15 trial.[abstract] Blood 2007; 110: 181a.Google Scholar

  • 31. Kimby E, Nygren P, Glimelius B, for the SBU group. A systemic overview of chemotherapy effects in acute myeloid leukaemia. Acta Oncologica 2001; 40 (2-3): 231-52.CrossrefGoogle Scholar

  • 32. Shen ZX, Shi ZZ, Fang J, et al. All-trans retinoic acid /As2O3 combination yields a high quality remission and survival in newly diagnosed acute promyelocytic leukemia. Proc Natl Acad Sci U S A 2004; 101 (15): 5328-35. http://dx.doi.org/10.1073/pnas.0400053101CrossrefGoogle Scholar

  • 33. Ghavamzadeh A, Alimoghaddam K, Ghaffari SH, et al. Treatment of acute promyelocytic leukemia without ATRA and/or chemotherapy. Ann Oncol 2006; 17 (1): 131-4. http://dx.doi.org/10.1093/annonc/mdj019CrossrefGoogle Scholar

  • 34. Mathews V, George B, Lakshmi KM, et al. Single-agent arsenic trioxide in the treatment of newly diagnosed acute promyelocytic leukemia: durable remission with minimal toxicity. Blood 2006; 107 (7): 2627-32. http://dx.doi.org/10.1182/blood-2005-08-3532CrossrefGoogle Scholar

  • 35. Estey E, Garcia-Manero G, Ferrajoli A, et al. Use of alltrans retinoic acid plus arsenic trioxide as an alternative to chemotherapy in untreated acute promyelocytic leukemia. Blood 2006; 107 (9): 3469-73. http://dx.doi.org/10.1182/blood-2005-10-4006CrossrefGoogle Scholar

  • 36. Sanz MA, Tallman MS, Lo-Coco F. Tricks of the trade for the appropriate management of acute promyelocytic leukemia. Blood 2005; 105 (8): 3019-25. http://dx.doi.org/10.1182/blood-2004-09-3475CrossrefGoogle Scholar

  • 37. Sanz MA, Lo-Coco F, Martin G, et al. Definition of relapse risk and role of non-anthracycline drugs for consolidation in patients with acute promyelocytic leukemia: a joint study of the PETHEMA and GIMEMA cooperative groups. Blood 2000; 96 (4): 1247-52.Google Scholar

  • 38. Lo-Coco F, Avvisati G, Vignetti M, et al. Front-line treatment of acute promyelocytic leukemia with AIDA induction followed by risk-adapted consolidation for adults younger than 61 years: results of the AIDA-2000 trial of the GIMEMA Group. Blood 2010;116 (17): 3171-9. http://dx.doi.org/10.1182/blood-2010-03-276196CrossrefGoogle Scholar

  • 39. Adés L, Sanz MA, Chevret S, et al. Treatment of newly diagnosed acute promyelocytic leukemia (APL): a comparison of French-Belgian-Swiss and PETHEMA results. Blood 2008; 111 (3): 1078-84. http://dx.doi.org/10.1182/blood-2007-07-099978CrossrefGoogle Scholar

  • 40. Sanz MA, Montesinos P, Rayón C, et al. Risk adapted tretament of acute promyelocytic leukemia based on all-trans retinoic acid and anthracycline with addition of cytarabine in consolidation therapy for high-risk patients: further improvements in treatment outcome. Blood 2010; 115 (25): 5137-46. http://dx.doi.org/10.1182/blood-2010-01-266007CrossrefGoogle Scholar

  • 41. Lo-Coco F, Avvisati G, Vignetti M, et al. Front-line treatment of acute promyelocytic leukemia with AIDA induction followed by risk-adapted consolidation for adults younger than 61 years: results of the AIDA-2000 trial of the GIMEMA group. Blood 2010; 116 (17): 3171-9. http://dx.doi.org/10.1182/blood-2010-03-276196CrossrefGoogle Scholar

  • 42. Powell BL, Moser B, Stock W, et al. Effects on consolidation with arsenic trioxide (As2O3) on event-free survival (EFS) and overall survival (OS) among patients with newly diagnosed acute promyelocytic leukemia (APL): North American Intergroup Protocol C9710. [meeting abstract] J Clin Oncol 2007; 25 (18) suppl 2:S 2.Google Scholar

  • 43. Illand HJ, Bradstock K, Supple SG, et al. All-trans-retinoic acid, idarubicin, and IV arsenic trioxide as initial therapy in acute promyelocytic leukemia (APML4). Blood 2012; 120 (8): 1570-80. http://dx.doi.org/10.1182/blood-2012-02-410746 CrossrefGoogle Scholar

  • 44. Breccia M, Diverio D, Noguera NI, et al. Clinico-biological features and outcome of acute promyelocytic leukemia patients with persistent polymerase chain reaction detectabile disease after the AIDA front-line induction and consolidation therapy. Haematologica 2004; 89: 29-33.Google Scholar

  • 45. Meloni G, Diverio D, Vignetti M, et al. Autologous bone marrow transplantation for acute promyelocytic leukemia in second remission: prognostic relevance of pretransplant minimal residual disease assessment by reverse- transcription polymerase chain reaction of the PML /RAR alpha fusion gene. Blood 1997; 90 (3): 1321-5.Google Scholar

  • 46. Román J, Martín C, Torres A, et al. Absence of detectable PML/RAR alpha fusion transcripts in long-term remission patients after BMT for acute promyelocytic leukemia. Bone Marrrow Transplant 1997; 19 (7): 679-83. http://dx.doi.org/10.1038/sj.bmt.1700712CrossrefGoogle Scholar

  • 47. Avvisati G, Lo-Coco F, Paoloni FP, et al. AIDA 0493 protocol for newly diagnosed acute promyelocytic leukemia: very long-term results and role of maintenance. Blood 2011; 117 (18): 4716-25. http://dx.doi.org/10.1182/blood-2010-08-302950CrossrefGoogle Scholar

  • 48. Sanz M, Matínez JA, Barragán E, et al. All-trans retinoic acid and low-dose chemotherapy for acute promyelocytic leukemia. Br J Haematol 2000; 109 (4): 896-97. http://dx.doi.org/10.1046/j.1365-2141.2000.109004896.xCrossrefGoogle Scholar

  • 49. Evans GD, Grimwade DJ. Extramedullary disease in acute promyelocytic leukemia. Leuk Lymphoma 1999; 33 (3-4): 219-29.Google Scholar

  • 50. Sanz MA, Vellenga E, Rayón C, et al. All-trans retinoic acid and anthracycline monochemotherapy for the treatment of elderly patients with acute promyelocytic leukemia. Blood 2004; 104 (12): 3490-3. http://dx.doi.org/10.1182/blood-2004-04-1642CrossrefGoogle Scholar

  • 51. Mandelli F, Latagliata R, Avvisati G, et al. Treatment of elderly patients (> or =60 years) with newly diagnosed acute promyelocytic leukemia. Results of the Italian multicenter group GIMEMA with ATRA and idarubicin (AIDA) protocols. Leukemia 2003; 17 (6): 1085-90. http://dx.doi.org/10.1038/sj.leu.2402932CrossrefGoogle Scholar

  • 52. Feusner JH, Gregory J. Acute promyelocytic leukemia in children. ASCO Educational Book; 2006.p. 577-81.Google Scholar

  • 53. Mann G, Reinhardt D, Ritter J, et al. Treatment with alltrans retinoic acid in acute promyelocytic leukemia reduces early deaths in children. Ann Hematol 2001; 80 (7): 417-22. http://dx.doi.org/10.1007/s002770100304CrossrefGoogle Scholar

  • 54. de Botton S, Coiteux V, Chevret S, et al. Outcome of childhood acute promyelocytic leukemia with all-transretinoic acid and chemotherapy. J Clin Oncol 2004; 22 (8): 1404-12. http://dx.doi.org/10.1200/JCO.2004.09.008CrossrefGoogle Scholar

  • 55. Testi AM, Biondi A, Lo-Coco F, et al. GIMEMA-AIEOP AIDA protocol for treatment of newly diagnosed acute promyelocytic leukemia (APL) in children. Blood 2005; 106 (2):447-53. http://dx.doi.org/10.1182/blood-2004-05-1971CrossrefGoogle Scholar

  • 56. Ortega JJ, Madero L, Martín L, et al. Treatmen twith alltrans retinoic acid and anthracycline monochemotherapy for children with acute promyelocytic leukemia: a multicenter study by the PETEMA Group. J Clin Oncol 2005; 23 (30): 7632-40. http://dx.doi.org/10.1200/JCO.2005.01.3359CrossrefGoogle Scholar

  • 57. Castaigne S, Lefebvre P, Chomienne C, et al. Effectiveness and pharmocokinetics of low-dose all-trans retionic acid (25 mg/m²) in acute promyelocytic leukemia. Blood 1993; 82 (12): 3560-3.Google Scholar

  • 58. Cardonick E, Iacobucci A. Use of chemotherapy during human pregnancy. Lancet Oncol 2004; 5 (5): 283-91. http://dx.doi.org/10.1016/S1470-2045(04)01466-4CrossrefGoogle Scholar

  • 59. Culligan DJ, Merriman L, Kell J, et al. The management of acute promyelocytic leukemia presenting during pregnancy. Clin Leukemia 2007; 1: 183-91. http://dx.doi.org/10.3816/CLK.2007.n.006CrossrefGoogle Scholar

  • 60. Mistry AR, Felix CA, Whitmarsh RJ, et al. DNA topoisomerase II in therapy-related acute promyelocytic leukemia. N Engl J Med 2005; 352 (15): 1529-38. http://dx.doi.org/10.1056/NEJMoa042715CrossrefGoogle Scholar

  • 61. Andersen MK, Larson RA, Mauritzson N, Schnittger S, Jhanwar SC, Pedersen-Bjergaard J. Balanced chromosome abnormalities inv (16) and t(15;17) in therapy related myelodysplastic syndromes and acute leukemia: report from an international workshop. Genes Chromosomes Cancer 2002; 33 (4): 395-400. http://dx.doi.org/10.1002/gcc.10043CrossrefGoogle Scholar

  • 62. Pedersen-Bjergaard J. Insights into leukemogenesis from therapy-related leukemia. N Engl J Med 2005; 352 (15): 1591-4. http://dx.doi.org/10.1056/NEJMe048336CrossrefGoogle Scholar

  • 63. Smith SM, Le Beau MM, Huo D, et al. Clinical-cytogenetic association in 306 patients with therapy-related myelodisplasia and myeloid leukemia: the University Chicago series. Blood 2003; 102 (1): 43-52. http://dx.doi.org/10.1182/blood-2002-11-3343CrossrefGoogle Scholar

  • 64. Beaumont M, Sanz M, Carli PM, et al. Therapy related acute promyelocytic leukemia: a report on 106 patients. J Clin Oncol 2003; 21 (11): 2123-37. http://dx.doi.org/10.1200/JCO.2003.09.072CrossrefGoogle Scholar

  • 65. Ledda A, Caocci G, Spinicci G, et al. Two new cases of acute promyelocytic leukemia following mitoxantrone treatment in patients with multiple sclerosis. Leukemia 2006; 20 (12): 2217-8. http://dx.doi.org/10.1038/sj.leu.2404443CrossrefGoogle Scholar

  • 66. Arnould C, Philippe C, Bourdon V, Grégoire MJ, Berger R, Jonveaux P. The signal transducer and activator of transcription STAT5b gene is a new partner of retinoic acid receptor alpha in acute promyelocytic leukemia-like leukemia. Hum Mol Genet 1999; 8 (9): 1741-9. http://dx.doi.org/10.1093/hmg/8.9.1741CrossrefGoogle Scholar

  • 67. Catalano A, Dawson MA, Somana K, et al. The PRKAR-1a gene is fused to RARA in a new variant acute promyelocytic leukemia. Blood 2007; 110 (12): 4073-76. http://dx.doi.org/10.1182/blood-2007-06-095554CrossrefGoogle Scholar

  • 68. Koken MH, Daniel MT, Gianni M, et al. Retinoic acid, but not arsenic trioxide, degradates the PLZF/RARα fusion protein, without inducing terminal differentiation or apoptosis, in a RA-therapy resistant t (11;17) (q23; q21) APL patient. Oncogene 1999; 18 (4): 1113-8. http://dx.doi.org/10.1038/sj.onc.1202414CrossrefGoogle Scholar

  • 69. Gallagher RE, Yeap BY, Bi W, et al. Quantitative real-time RT-PCR analysis of PML-RAR alpha mRNA in acute promyelocytic leukemia: assessment of prognostic sig nificance in adult patients from intergroup protocol 0129. Blood 2003; 101 (7): 2521-8. http://dx.doi.org/10.1182/blood-2002-05-1357CrossrefGoogle Scholar

  • 70. Lengfelder E, Saussele S, Haferlach T, et al. Do patients with acute promyelocytic leukemia (APL) really have a good prognosis? Risk factors for early death and complications in the era of all-trans retinoic acid (ATRA). Results of the AMLCG[abstract 66]. Onkologie 2002; 25 suppl4: S19.Google Scholar

  • 71. Douer D, Zickl LN, Sciffer CA, et al. All-trans retinoic acid and late relapse in acute promyelocytic leukemia: very long-time follow up of North American Intergroup Study 10129. Leuk Res 2013; 37 (7): 795-801. http://dx.doi.org/10.1016/j.leukres.2013.03.001CrossrefGoogle Scholar

  • 72. Diverio D, Rossi V, Avvisati G, et al. Early detection of relapse by prospective reverse-polymerase chain reaction analysis of the PML/RARα fusion gene in patients with acute promyelocytic leukemia enrolled in the GIMEMA- AIEOP multicenter AIDA trial. Blood 1998; 92: 784-9.Google Scholar

  • 73. Santamaria C, Chillón MC, Fernández C, et al. Using quantification of the PML-RARalpha transcript to stratify the risk relapse in patients with acute promyelocytic leukamia. Haematologica 2007; 92 (3): 315-22. http://dx.doi.org/10.3324/haematol.10734CrossrefGoogle Scholar

  • 74. Grimwade D, Jovanovic JV, Hills RK, et al. Prospective minimal residual disease monitoring to predict relapse of acute promyelocytic leukemia and direct pre-emptive arsenic trioxide therapy. J Clin Oncol 2009; 27 (22): 3650-8. http://dx.doi.org/10.1200/JCO.2008.20.1533CrossrefGoogle Scholar

  • 75. Esteve J, Escoda L, Martin G, et al. Outcome of patients with acute promyelocytic leukemia failing to frontline treatment with all-trans retionic acid and anthracycline based chemotherapy (PETHEMA protocols LPA 96 and LPA 99): benefit of an early intervention. Leukemia 2007; 21 (3): 446-52. http://dx.doi.org/10.1038/sj.leu.2404501CrossrefGoogle Scholar

  • 76. Douer D. New advances in the acute promyelocytic leukemia. Int J Hematol 2002; 76 (suppl2): 179-87. http://dx.doi.org/10.1007/BF03165115CrossrefGoogle Scholar

  • 77. Shen Z-X, Chen G-Q, Ni J-H, et al. Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): II. Clinical efficacy and pharmacokinetics in relapsed patients. Blood 1997; 89 (9): 3354-60.Google Scholar

  • 78. Au WY, Lie AK, Chim CS, et al. Arsenic trioxide in comparison with chemotherapy and bone marrow transplantation for the treatment of relapsed acute promyelocytic leukemia. Ann Oncol 2003; 14 (5): 752-57. http://dx.doi.org/10.1093/annonc/mdg208CrossrefGoogle Scholar

  • 79. Lazo G, Kantarjian H, Estey E, et al. Use of arsenic trioxide (As2O3) in the treatment of patients with acute promyelocytic leukemia: the M.D. Anderson experience. Cancer 2003; 97 (9): 2218-24. http://dx.doi.org/10.1002/cncr.11314CrossrefGoogle Scholar

  • 80. Niu C, Yan H, Yu T, et al. Studies on treatment of acute promyelocytic leukemia experiance with arsenic trioxide: remission induction, follow up, and molecular monitoring in 11 newly diagnosed and 47 relapsed acute promyelocytic leukemia patients. Blood 1999; 94 (10): 3315-24.Google Scholar

  • 81. Raffoux E, Rousselot P, Poupon J, et al. Combined treatment with arsenic trioxide and all-trans retionic acid in patients with relapsed acute promyelocytic leukemia. J Clin Oncol 2003; 21 (12): 2326-34. http://dx.doi.org/10.1200/JCO.2003.01.149CrossrefGoogle Scholar

  • 82. Shigeno K, Naito K, Sahara N, et al. Arsenic-trioxide therapy in relapsed or refractory Japanese patients with acute promyelocytic leukemia: updated outcomes of the phase II study and postremission therapies. Int J Hematol 2005; 82 (3): 224-9. http://dx.doi.org/10.1532/IJH97.05044CrossrefGoogle Scholar

  • 83. Chen Z, Zhao WL, Shen ZX, et al. Arsenic trioxide and acute promyelocytic leukemia: clinical and biological. Curr Top Microbiol Immunol 2007; 313: 129-44. http://dx.doi.org/10.1007/978-3-540-34594-7_8CrossrefGoogle Scholar

  • 84. Tallman MS. Treatment of relapsed or refractory acute promyelocytic leukemia. Best Pract Res Clin Haematol 2007; 20: 57-65. http://dx.doi.org/10.1016/j.beha.2006.11.002CrossrefGoogle Scholar

  • 85. Wang G, Li W, Cui J, et al.An efficient therapeutic approach to patients with acute promyelocytic leukemia using a combination of arsenic trioxide with low-dose alltrans retinoic acid. Hematol Oncol 2004; 22 (2): 63-71. http://dx.doi.org/10.1002/hon.728CrossrefGoogle Scholar

  • 86. Au WY, Chim CS, Lie AK, Kwong YL. Combined arsenic trioxide and all-trans retionic acid treatment for acute promyelocytic leukemia reccuring from previous relapses successfully treated using arsenic trioxide. Br J Haematol 2002; 117 (1): 130-2. http://dx.doi.org/10.1046/j.1365-2141.2002.03409.xCrossrefGoogle Scholar

  • 87. Douer D, Hu W, Giralt S, et al. Arsenic trioxide (trisenox) therapy for acute promyelocytic leukemia in setting of hematopoietic stem cell transplantation. Oncologist 2003; 8 (2): 132-40. http://dx.doi.org/10.1634/theoncologist.8-2-132CrossrefGoogle Scholar

  • 88. Pemmaraju N, Tanaka MF, Ravandi F, et al. Outcomes in patient with relapsed or refractory acute promyelocytic leukemia treated with or without autologous or allogeneic hematopoietic stem cell transplantation. Clin Lymphoma Myeloma Leuk 2013; 13 (4): 485-92. http://dx.doi.org/10.1016/j.clml.2013.02.023CrossrefGoogle Scholar

  • 89. Lo-Coco F, Cimino G, Breccia M, et al. Gemtuzumab ozogamicin (Mylotarg) as a single agent for molecularly relapsed acute promyelocytic leukemia. Blood 2004; 104 (7): 1995-9. http://dx.doi.org/10.1182/blood-2004-04-1550CrossrefGoogle Scholar

  • 90. Takeshita A, Shinjo K, Naito K, et al. Efficacy of gemtuzumab ozogamicin on ATRA and arsenic-resistant acute promyelocytic leukemia (APL) cells. Leukemia 2005; 19 (8): 1306-11. http://dx.doi.org/10.1038/sj.leu.2403807CrossrefGoogle Scholar

  • 91. Specchia G, Lo-Coco F, Vignetti M, et al. Extramedullary involvement at relapsed acute promyelocytic leukemia patients treated or not with ATRA: a report by the GIMEMA Group. J Clin Oncol 2001; 19 (20): 4023 -8. Google Scholar

  • 92. de Botton S, Sanz MA, Chevret S, et al. Extramedullary relapse in acute promyelocytic leukemia treated with all-trans retinoic acid and chemotherapy. Leukemia all-trans retinoic acid and chemotherapy. Leukemia 2006; 20(1):35-41. http://dx.doi.org/10.1038/sj.leu.2404006 CrossrefGoogle Scholar

About the article

Published Online: 2014-03-25

Published in Print: 2014-03-01

Citation Information: Acta Facultatis Medicae Naissensis, Volume 31, Issue 1, Pages 17–28, ISSN (Print) 2217-2521, DOI: https://doi.org/10.2478/afmnai-2014-0002.

Export Citation

This content is open access.

Comments (1)

Please log in or register to comment.
Log in
  • I like my work, even after many views. The data at the moment has changed for a little bit. The studies now concluded that ATRA+ATO as front-line th in high risk patients are excellent choice for management of the disease

    posted by: Ivan Petkovic on 2014-10-01 02:03 PM (Europe/Berlin)